EGFR and non-small cell lung carcinoma: Similarly, the HERTHENA-Lung02 phase 3 study evaluating HER3-DXd vs. platinum-based chemotherapy in EGFR-mutant NSCLC after disease progression on a third-generation TKI reported adjudicated drug-related ILD in 5% of patients (n = 14; 11 grade 1/2, 1 grade 3, and 2 grade 5) in the HER3-DXd arm [24].